Bausch + Lomb Shares Rise in U.S. Pre-market After Posting Increase in Q4 Adjusted Profit, Revenue

Bausch + Lomb Corporation (NYSE: BLCO) shares rose in U.S. pre-market trading on Tuesday following the company's announcement of a 11% increase in Q4 adjusted profit and a 9% increase in revenue compared to the same period last year. The strong financial performance was driven by broad-based growth across all segments, geographies, and key franchises, as well as solid execution in the dry eye portfolio and double-digit revenue growth in the contact lens business.

The company reported total revenue of $1.280 billion for the fourth quarter of 2024, compared to $1.173 billion in the fourth quarter of 2023. Excluding the unfavorable impact of foreign exchange, revenue increased by approximately 11% on a constant currency basis. For the full year of 2024, total revenue was $4.791 billion, compared to $4.146 billion in the full year of 2023. Excluding the unfavorable impact of foreign exchange, revenue increased by approximately 17% on a constant currency basis.

Bausch + Lomb's strong financial performance was driven by several key factors. The company's commitment to long-term, profitable growth and its refocused pipeline filled with promise and potential have enabled it to enhance the standard of care for patients across the spectrum of eye health needs. This strategic focus has allowed Bausch + Lomb to deliver broad-based growth across all segments, geographies, and key franchises, as evidenced by its strong financial performance in 2024.



The company's strategic focus on eye health and biotech has contributed significantly to its resilience in a shifting market. Bausch + Lomb's commitment to innovation and market penetration in the dry eye market, as well as its strong brand in the contact lens market, has enabled it to maintain growth despite market shifts. The company's ability to navigate market shifts and maintain growth is a testament to its strategic vision and execution.



In conclusion, Bausch + Lomb's strong financial performance in the fourth quarter of 2024, driven by broad-based growth across all segments and a commitment to innovation and market penetration, has contributed to the company's resilience in a shifting market. The company's strategic focus on eye health and biotech, as well as its commitment to long-term, profitable growth, has enabled it to deliver strong financial results and maintain growth despite market shifts. As the company continues to execute on its strategic vision, investors can expect Bausch + Lomb to remain a strong performer in the eye health market.